Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes

Angeliki Meritsi; Dimitra Latsou; Emanuel Manesis; Ilias Gatos; Ioannis Theotokas; Pavlos Zoumpoulis; Stamatia Rapti; Eustathios Tsitsopoulos; Hariklia Moshoyianni; Spilios Manolakopoulos; Dimitrios Pektasides; Anastasia Thanopoulou

doi:10.2337/cd21-0104

Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes

Clin Diabetes. 2022 Summer;40(3):327-338. doi: 10.2337/cd21-0104.

Affiliations

¹ Diabetic Center, 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Social and Educational Policy, University of Peloponnese, Corinth, Greece.
³ Liver Unit, Euroclinic, Athens, Greece.
⁴ Diagnostic Echotomography, SA, Kifissia, Athens, Greece.
⁵ Laboratory of Molecular Genetics, Biomedicine, SA, Athens, Greece.
⁶ Biomedicine, SA, Athens, Greece.
⁷ Liver and Gastrointestinal Unit, 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
⁸ 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.